Cazenave JP - Search Results

1

Evaluation of soluble glycoprotein V as a marker of venous thromboembolism.

Gayol S, Kirchgesner T, Kopferschmitt J, Meyer N, Sauleau E, Wiesel ML, Cazenave JP, Gachet C, Lanza F. Gayol S, et al. Among authors: cazenave jp. Thromb Haemost. 2012 Jan;107(1):184-7. doi: 10.1160/TH11-09-0630. Epub 2011 Nov 24. Thromb Haemost. 2012. PMID: 22116210 No abstract available.

2

Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies.

Aleil B, Meyer N, Wolff V, Kientz D, Wiesel ML, Gachet C, Cazenave JP, Lanza F. Aleil B, et al. Among authors: cazenave jp. Thromb Haemost. 2006 Oct;96(4):505-11. Thromb Haemost. 2006. PMID: 17003930

3

Plasma levels of soluble platelet glycoprotein V are linked to fasting blood glucose in patients with type 2 diabetes.

Aleil B, Kessler L, Meyer N, Wiesel ML, Simeoni J, Cazenave JP, Pinget M, Gachet C, Lanza F. Aleil B, et al. Among authors: cazenave jp. Thromb Haemost. 2008 Oct;100(4):713-5. Thromb Haemost. 2008. PMID: 18841299 No abstract available.

4

Studies of alpha 2-adrenergic receptors of intact and functional washed human platelets by binding of 3H-dihydroergocryptine and 3H-yohimbine--correlation of 3H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation.

Lanza F, Cazenave JP. Lanza F, et al. Among authors: cazenave jp. Thromb Haemost. 1985 Aug 30;54(2):402-8. Thromb Haemost. 1985. PMID: 3001964

5

High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease.

Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C. Aleil B, et al. Among authors: cazenave jp. Thromb Haemost. 2005 Oct;94(4):886-7. doi: 10.1160/TH05-04-0886. Thromb Haemost. 2005. PMID: 16270649 Clinical Trial. No abstract available.

6

Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.

Wolff V, Aleil B, Giroud M, Lorenzini JL, Meyer N, Wiesel ML, Cazenave JP, Lanza F. Wolff V, et al. Among authors: cazenave jp. Stroke. 2005 Mar;36(3):e17-9. doi: 10.1161/01.STR.0000155738.02753.4d. Epub 2005 Feb 3. Stroke. 2005. PMID: 15692116

7

A high concentration of ADP induces weak platelet granule secretion independently of aggregation and thromboxane A2 production.

Lantz N, Hechler B, Ravanat C, Cazenave JP, Gachet C. Lantz N, et al. Among authors: cazenave jp. Thromb Haemost. 2007 Nov;98(5):1145-7. doi: 10.1160/th07-06-0392. Thromb Haemost. 2007. PMID: 18000625 No abstract available.

8

Electrophoretic studies on molecular defects of von Willebrand factor and platelet glycoprotein IIb-IIIa with antibodies produced in egg yolk from laying hens.

Toti F, Gachet C, Ohlmann P, Stierlé A, Grunebaum L, Wiesel ML, Cazenave JP. Toti F, et al. Among authors: cazenave jp. Haemostasis. 1992;22(1):32-40. doi: 10.1159/000216289. Haemostasis. 1992. PMID: 1521825

9

Normal ADP-induced aggregation and absence of dissociation of the membrane GP IIb-IIIa complex of intact rat platelets pretreated with EDTA.

Gachet C, Stierlé A, Ohlmann P, Lanza F, Hanau D, Cazenave JP. Gachet C, et al. Among authors: cazenave jp. Thromb Haemost. 1991 Aug 1;66(2):246-53. Thromb Haemost. 1991. PMID: 1771618

10

An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis.

Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. Freyssinet JM, et al. Among authors: cazenave jp. Thromb Haemost. 1986 Jun 30;55(3):309-13. Thromb Haemost. 1986. PMID: 3018955

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

447 results

Search Page

Filters